...
首页> 外文期刊>Intensive care medicine >Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.
【24h】

Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection.

机译:严重甲型H1N1流感v感染的患者在ICU入院时使用早期皮质类固醇治疗。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: Early use of corticosteroids in patients affected by pandemic (H1N1)v influenza A infection, although relatively common, remains controversial. METHODS: Prospective, observational, multicenter study from 23 June 2009 through 11 February 2010, reported in the European Society of Intensive Care Medicine (ESICM) H1N1 registry. RESULTS: Two hundred twenty patients admitted to an intensive care unit (ICU) with completed outcome data were analyzed. Invasive mechanical ventilation was used in 155 (70.5%). Sixty-seven (30.5%) of the patients died in ICU and 75 (34.1%) whilst in hospital. One hundred twenty-six (57.3%) patients received corticosteroid therapy on admission to ICU. Patients who received corticosteroids were significantly older and were more likely to have coexisting asthma, chronic obstructive pulmonary disease (COPD), and chronic steroid use. These patients receiving corticosteroids had increased likelihood of developing hospital-acquired pneumonia (HAP) [26.2% versus 13.8%, p < 0.05; odds ratio (OR) 2.2, confidence interval (CI) 1.1-4.5]. Patients who received corticosteroids had significantly higher ICU mortality than patients who did not (46.0% versus 18.1%, p < 0.01; OR 3.8, CI 2.1-7.2). Cox regression analysis adjusted for severity and potential confounding factors identified that early use of corticosteroids was not significantly associated with mortality [hazard ratio (HR) 1.3, 95% CI 0.7-2.4, p = 0.4] but was still associated with an increased rate of HAP (OR 2.2, 95% CI 1.0-4.8, p < 0.05). When only patients developing acute respiratory distress syndrome (ARDS) were analyzed, similar results were observed. CONCLUSIONS: Early use of corticosteroids in patients affected by pandemic (H1N1)v influenza A infection did not result in better outcomes and was associated with increased risk of superinfections.
机译:简介:虽然流行病相对较普遍,但在大流行(H1N1)v甲型流感感染患者中早期使用皮质类固醇仍存在争议。方法:2009年6月23日至2010年2月11日进行的前瞻性,观察性,多中心研究在欧洲重症监护医学会(ESICM)H1N1注册中心进行了报道。结果:分析了入院重症监护病房(ICU)的220例患者,这些患者具有完整的结局数据。 155例中有创机械通气(70.5%)。其中有67名(30.5%)患者死于ICU,而在医院死亡75名(34.1%)。一百二十六(57.3%)的患者在入ICU时接受了皮质类固醇治疗。接受皮质类固醇激素治疗的患者年龄较大,更有可能并存哮喘,慢性阻塞性肺疾病(COPD)和长期使用类固醇激素。这些接受皮质类固醇激素治疗的患者发生医院获得性肺炎(HAP)的可能性增加[26.2%对13.8%,p <0.05;比值比(OR)2.2,置信区间(CI)1.1-4.5]。接受皮质类固醇激素治疗的患者的ICU死亡率显着高于未接受皮质类固醇激素治疗的患者(46.0%对18.1%,p <0.01; OR 3.8,CI 2.1-7.2)。经校正严重程度和潜在混杂因素的Cox回归分析表明,早期使用皮质类固醇与死亡率无显着相关性[危险比(HR)1.3,95%CI 0.7-2.4,p = 0.4],但仍与死亡率的增加相关HAP(OR 2.2,95%CI 1.0-4.8,p <0.05)。当仅分析发生急性呼吸窘迫综合征(ARDS)的患者时,观察到相似的结果。结论:在甲型H1N1流感大流行性流感感染患者中早期使用皮质类固醇激素并不能带来更好的预后,而且与增加感染的风险有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号